<DOC>
	<DOC>NCT02375633</DOC>
	<brief_summary>A Multicenter, Randomized, Double-blinded, Parallel, Active-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DW-330SR2 and Pelubiprofen in Chronic Back Pain Patients.</brief_summary>
	<brief_title>Phase 3 Study of DW-330SR2 and Pelubiprofen in Chronic Back Pain Patients</brief_title>
	<detailed_description />
	<mesh_term>Back Pain</mesh_term>
	<criteria>More than 12 weeks by the time the trial started , and low back pain that requires analgesia administration. Class 1 or 2 back pain patients along Quebec Task Force Classification Patients with pain at least 40mm test results at visit2 The voluntary or legal guardian 's written consent to participate in this clinical trial subjects Severe gastrointestinal disease, heart disease, high blood pressure patients Patients with secondary causes are obvious Within 24 weeks patient who has back surgery before clinical trial participation Within 4 weeks patient who experienced psychotropic drugs, a narcotic analgesic dosage that may affect the pain sensation Within 4 weeks patient who treated steroid drug by oral or injection Within 2 weeks patient who treated MAO inhibition drugs Patients with severe respiratory depression status</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>